Search research articles
Contact Us
Filters
Showing results (61-70 of 212) with videos related to
Page
of 22
Sort By:
American Heart Journal
|
December 15, 2010
Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial
Tjeerd E van Rees Vellinga, Ron J G Peters, Salim Yusuf, et al.
The Canadian Journal of Cardiology
|
April 11, 2016
A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score
Shamir R Mehta, John W Eikelboom, Purnima Rao-Melacini, et al.
The Canadian Journal of Cardiology
|
November 29, 2011
Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 1: non-ST-segment elevation ACS
David H Fitchett, Pierre Theroux, James M Brophy, et al.
American Heart Journal
|
December 13, 2005
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes
, Shamir R Mehta, Salim Yusuf, et al.
European Heart Journal
|
February 5, 2008
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial
Ron J G Peters, Campbell Joyner, Jean-Pierre Bassand, et al.
Annals of Internal Medicine
|
September 6, 2007
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes
Keith A A Fox, Jean-Pierre Bassand, Shamir R Mehta, et al.
BMC Surgery
|
October 16, 2015
Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials
Subodh Verma, Shaun G Goodman, Shamir R Mehta, et al.
The New England Journal of Medicine
|
October 29, 2010
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment
Guillaume Paré, Shamir R Mehta, Salim Yusuf, et al.
JAMA Cardiology
|
May 21, 2020
Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-analysis
Kevin R Bainey, Thomas Engstrøm, Pieter C Smits, et al.
Clinical Biochemistry
|
April 19, 2020
Clinical evaluation of Ortho Clinical Diagnostics high-sensitivity cardiac Troponin I assay in patients with symptoms suggestive of acute coronary syndrome
Peter A Kavsak, Shawn E Mondoux, Jonathan Sherbino, et al.
Page
of 22
Search research articles
Search
Showing results (61-70 of 212) with videos related to
Sort By:
Page
of 22
American Heart Journal
|
December 15, 2010
Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial
Tjeerd E van Rees Vellinga, Ron J G Peters, Salim Yusuf, et al.
The Canadian Journal of Cardiology
|
April 11, 2016
A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score
Shamir R Mehta, John W Eikelboom, Purnima Rao-Melacini, et al.
The Canadian Journal of Cardiology
|
November 29, 2011
Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 1: non-ST-segment elevation ACS
David H Fitchett, Pierre Theroux, James M Brophy, et al.
American Heart Journal
|
December 13, 2005
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes
, Shamir R Mehta, Salim Yusuf, et al.
European Heart Journal
|
February 5, 2008
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial
Ron J G Peters, Campbell Joyner, Jean-Pierre Bassand, et al.
Annals of Internal Medicine
|
September 6, 2007
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes
Keith A A Fox, Jean-Pierre Bassand, Shamir R Mehta, et al.
BMC Surgery
|
October 16, 2015
Should dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trials
Subodh Verma, Shaun G Goodman, Shamir R Mehta, et al.
The New England Journal of Medicine
|
October 29, 2010
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment
Guillaume Paré, Shamir R Mehta, Salim Yusuf, et al.
JAMA Cardiology
|
May 21, 2020
Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-analysis
Kevin R Bainey, Thomas Engstrøm, Pieter C Smits, et al.
Clinical Biochemistry
|
April 19, 2020
Clinical evaluation of Ortho Clinical Diagnostics high-sensitivity cardiac Troponin I assay in patients with symptoms suggestive of acute coronary syndrome
Peter A Kavsak, Shawn E Mondoux, Jonathan Sherbino, et al.
Page
of 22